19th Ave New York, NY 95822, USA
Join Now

Grup de Tumors del Tracte Gastrointestinal

Portfolio Item Grup de Tumors del Tracte Gastrointestinal
RECERCA CLÍNICA

El Grup de Tumors del Tracte Gastrointestinal del VHIO, liderat per Elena Élez, reuneix una àmplia experiència tant en tumors colorectals com gastroesofàgics, integrant recerca clínica i translacional per millorar l’atenció als pacients. La nostra activitat se centra a identificar nous biomarcadors pronòstics i predictius, comprendre els mecanismes de resistència als tractaments i desenvolupar estratègies terapèutiques innovadores en les diferents fases de la malaltia.

En càncer colorectal (CCR), el grup gaudeix de reconeixement internacional pel seu lideratge en la malaltia amb mutació de BRAF, un subtipus associat a característiques clinicopatològiques agressives. Els nostres investigadors han contribuït a estudis de referència com l’assaig BREAKWATER de fase III, que va donar suport a l’aprovació d’encorafenib en combinació amb cetuximab i quimioteràpia en primera línia, i continuem ampliant les opcions terapèutiques mitjançant assaigs promoguts per investigadors que exploren noves combinacions. També hem tingut un paper clau en el desenvolupament i l’aprovació de múltiples tractaments per al CCR metastàtic, inclosos els inhibidors de punts de control immunitari per als tumors MSI-H i els agents dirigits en la malaltia refractària. Paral·lelament, estem ampliant els esforços de recerca en el CCR d’aparició precoç, amb l’objectiu d’esclarir el paper de les exposicions ambientals, la microbiota i la immunitat de l’hoste en la formació dels tumors.

El microbioma constitueix una prioritat central i transversal de recerca, amb estudis que exploren el seu paper en el desenvolupament del càncer, la resposta al tractament i la toxicitat. Aquests treballs es basen en enfocaments multidisciplinaris que integren l’anàlisi de mostres biològiques i l’avaluació dels hàbits alimentaris, inclòs el desenvolupament d’un qüestionari validat de freqüència de consum d’aliments per estudiar les interaccions entre nutrició i microbioma en la població espanyola. En càncer de recte, la nostra recerca se centra a optimitzar les estratègies perioperatòries en la malaltia localitzada, inclosos assaigs clínics com l’estudi DUREC, que avalua la incorporació de la immunoteràpia a la quimioradioteràpia estàndard, juntament amb projectes translacionals que investiguen la influència de la microbiota en l’eficàcia del tractament.

En els càncers gastroesofàgics, el programa està dedicat a millorar els resultats en els tumors d’esòfag, de la unió gastroesofàgica i d’estómac mitjançant la innovació terapèutica i la medicina de precisió. Hem contribuït a assaigs fonamentals com MATTERHORN, que va donar suport a la incorporació de la immunoteràpia en el context perioperatori, i DESTINY-Gastric04, que va establir trastuzumab deruxtecan com a tractament estàndard de segona línia en la malaltia HER2 positiva. La nostra recerca també se centra en noves dianes emergents, com CLDN18.2, a partir de la nostra participació en el desenvolupament de zolbetuximab i avançant en l’avaluació d’agents de nova generació en assaigs de fases inicials.

Els esforços de recerca translacional en càncer gastroesofàgic inclouen la identificació de biomarcadors predictius de resposta a la immunoteràpia, com la signatura d’expressió gènica VIGex, així com l’estudi de l’heterogeneïtat del microambient tumoral i de la coincidència entre biomarcadors per perfeccionar la priorització dels tractaments. Una de les pedres angulars de la nostra estratègia és el desenvolupament d’assaigs promoguts per investigadors, inclòs l’estudi RILVE de fase II, que avalua rilvegostomig, un nou anticòs biespecífic dirigit contra PD-1 i TIGIT, en càncer gàstric avançat.

En totes dues àrees de malaltia, posem un èmfasi especial en la resistència al tractament i en les necessitats clíniques no cobertes en estadis avançats. Altres línies de recerca inclouen l’estudi de la caquèxia i la sarcopènia associades al càncer mitjançant enfocaments radiòmics en poblacions tractades amb immunoteràpia. Gràcies a aquest enfocament integral i integrat —que abasta el descobriment de biomarcadors, la recerca del microbioma, l’optimització perioperatòria i el desenvolupament de nous fàrmacs—, el nostre grup es troba en una posició privilegiada per contribuir a definir nous estàndards assistencials i impulsar estratègies terapèutiques de nova generació en els càncers gastrointestinals.

Elena Élez
Cap de grup
Biosketch

Liníes de recerca

  • Impulsar el desenvolupament de fàrmacs per als càncers gastrointestinals mitjançant la participació en assaigs clínics internacionals i el lideratge d’estudis promoguts per investigadors i de fases inicials, inclosos dissenys innovadors com els estudis de finestra d’oportunitat.
  • Avançar en l’oncologia de precisió integrant el descobriment, la validació i la implementació de biomarcadors amb estratègies multiòmiques i de biòpsia líquida, amb l’objectiu d’optimitzar la selecció de pacients i monitorar l’evolució de la malaltia.
  • Esclarir els mecanismes de resistència primària i adquirida als tractaments contra el càncer, amb una atenció especial al càncer colorectal amb mutació de BRAF i als tumors gastroesofàgics refractaris, per identificar noves vulnerabilitats terapèutiques.
  • Desenvolupar i optimitzar estratègies terapèutiques dirigides i basades en el sistema immunitari per a subgrups molecularment definits de càncer gastroesofàgic —com HER2 i CLDN18.2—, inclosa la incorporació de nous agents i combinacions, i integrar aquests enfocaments tant en el context perioperatori com en la malaltia avançada.
  • Investigar el càncer colorectal d’aparició precoç com una prioritat central de recerca, centrant-nos en els seus mecanismes biològics subjacents i en el paper de les exposicions ambientals en la formació dels tumors.
  • Caracteritzar el paper del microbioma i dels factors ambientals en el càncer, inclòs el seu impacte en el desenvolupament tumoral, la resposta al tractament i la toxicitat, i avaluar les interaccions entre nutrició i microbioma mitjançant eines dietètiques validades.
  • Caracteritzar la biologia de la malaltia en els diferents estadis, inclosa la progressió metastàtica —per exemple, les metàstasis hepàtiques del càncer colorectal— i la dinàmica del microambient tumoral, per perfeccionar l’estratificació pronòstica i la priorització dels tractaments.
  • Investigar la caquèxia i la sarcopènia associades al càncer, especialment en el càncer gastroesofàgic i en poblacions tractades amb immunoteràpia, per millorar els resultats clínics i la qualitat de vida dels pacients.

Equip

Cap de grup
Elena Élez
Equipo de Cáncer de Colon: Oncólogos médicos e investigadores clínicos - càncer colorrectal
Iosune Baraibar, Marta Rodríguez, Francisco Javier Ros, Francesc Salvà, Clara Salvà, Nadia Saoudí
Equipo de Cáncer de Colon: Oncólogos médicos e investigadores clínicos - càncer gastroesofàgic
Daniel Acosta, Eduardo Terán
Infermera de Recerca oncològica
Ariadna Garcia
Nutricionista
Adriana Alcaraz
Colon Taskforce Manager
Mireia Sanchís
Gestora de mostres
Inés Suárez

Projectes

  1. Exploring the feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumours (Immune4ALL). PI: Elena Élez. Grantor: Carlos III Health Institute. Duration: 01/01/2023 – 31/12/2025.
  2. A precision medicine trial leveraging blood-based tumour genomics to optimise treatment in operable stage iii and high-risk stage ii colon cancer patients – the Sagittarius Trial. PI: Elena Élez. Grantor: Horizon Europe. Duration: 01/07/2023 – 30/06/2028.
  3. Multi-target approach including anti-angiogenic agent to overcome treatment resistance in BRAF mutant metastatic colorectal setting. PI: Elena Élez. Grantor: Carlos III Health Institute. Duration: 01/01/2022 – 31/12/2025.
  4. Identification and validation of mechanisms of resistance and response to targeted therapies in patients with metastatic colorectal cancer with BRAFV600E mutation. Grantor: CRIS Cancer Foundation. PI: Elena Élez. Duration:  01/12/2021 – 31/12/2025.
  5. Identification and validation of sensitivity signatures and mechanisms of resistance and response to targeted therapies and immunotherapy in patients with advanced colorectal cancer. Grantor: Carlos III Health Institute. Duration: 01/01/2021 – 30/06/2025.
  6. BioPrinted hydROgel MicrofluIdicS to mimic patient-specific tumour mEtastatic (PROMISE). Grantor: «La Caixa» Foundation. Duration: 01/12/2020 – 30/05/2025.
  7. OPTIMISTICC: OPportunity To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer. PI: Josep Tabernero. Grantor: Grand Challenge Cancer Research UK. Duration: 01/01/2019 – 30/12/2025.
  8. Identification and Validation of Mechanisms of Resistance and Response to Targeted Therapies in BRAFV600E Metastatic Colorectal Cancer. PI: Elena Élez. Grantor: TTD Duration: 01/03/2022 – 28/02/2025.
  9. Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer stage II-III (CIRCULATE-SPAIN). PI: Elena Élez. Grantor: Carlos III Health Institute. Duration: 2021 – 2025.
  10. Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors: the SERPENTINE clinical trial (Single cEll pRofiling PErsistaNce To ImmuNothErapy). PI: Elena Élez. Grantor: AstraZeneca Farmacéutica Spain, S.A. Duration: 11/01/2022 – 31/03/2026.
  11. Evaluación de las estructuras linfoides terciarias (TLS) como biomarcador en el cáncer colorrectal metastásico tratado con combinaciones de puntos de control inmunitarios. PI: Elena Élez. Grantor: Becas SEOM para Proyectos de Investigación Traslacional en Inmuno-oncología 2024. Duration: 01/12/2023-30/11/2025.
  12. Single-cell resolution of primary CRC microenvironment and matched liver tumor metastasis (LimeCop). PI: Elena Élez. Grantor: MEDIMMUNE LLC. Duration: 09/06/2023 – 31/12/2025.
  13. Biomarker identification in patients with BRAF mutant metastatic colorectal cancer to guide treatment strategy and overcome primary/adquired restances to BRAF Inhibitor-targeted agents – BRAFsistance. PI: Elena Élez. Grantor: CRIS Cancer Foundation. Duration: 01/05/2024 – 30/04/2029.
  14. Identification of T cell receptors targeting hotspot mutations in common driver oncogenes from tumor specimens of mismatch repair proficient colorectal carcinoma patients. PI: Elena Élez. Grantor: AstraZeneca UK Ltd. Duration: 14/11/2024 – 14/11/2026.
  15. Identification and Analysis of Hepatic Transcriptional Regulators in Liver Metastasis of Colorectal Cancer (COHET project). PI: Elena Élez. Grantor: Gilead Sciences. Duration: 2025-2027.
  16. Colorectal cancer – Stratification of Therapies through Adaptive Responses (CRC-STARS). PI: Josep Tabernero. Grantor: Cancer Research UK. Duration: 04/2025-03/2030
  17. EGFR Ligand-Based Patients Hyperselection in Neoadjuvant Therapy: Transforming Treatment Strategies for Localized Colon Cancer through FOxTROT8 clinical trial. PI: Elena Élez. Grantor: Asociación Española Contra el Cáncer (AECC). Duration: 2025-2030
  18. VHIO23004 (REFISH) A Phase 2, Single-Arm study of encorafenib plus cetuximab as rechallenge treatment of BRAF V600E-mutant metastatic colorectal cancer patients after previous therapy with BRAF inhibitors-based combinations: the REFISH trial. PI: Elena Élez. Grantor: VHIO
  19. Validation of the VIGex gene expression signature as a predictive biomarker for immune checkpoint inhibitors in patients with gastroesophageal adenocarcinoma. PI: Daniel Acosta. Grantor: SEOM Duration: 2024 – 2026
  20. Local and systemic immune modulation by rilvegostomig in advanced gastric cancer (RILVE Project). PI: Dr. Elena Élez and Dr. Eduardo Terán. Collaborator: AstraZeneca (Partners of Choice Program). Phase: II (Window-of-opportunity)  Duration: 2024-2026. Investigator-initiated trial evaluating the pharmacodynamic and immunological effects of the PD-1/TIGIT bispecific antibody rilvegostomig in first-line gastric cancer through comprehensive translational endpoints including serial tumor biopsies and peripheral immune monitoring.
  21. INMUNO-CGM: Immunonutritional profile and body composition as predictors of response and toxicity to immunotherapy in metastatic gastric cancer. PR(AG)618/2025. PI: Eduardo Terán and Richard Mast. Duration: 2026-2028.
  22. Expresión de Claudina 18.2 en tumores gastroesofágicos:  solapamiento de biomarcadores y su impacto pronóstico asociado. PR(AG)533/2025. PI: Eduardo Terán. Duration: 2026-2028.
  23. Ampliando el beneficio de la inmunoterapia en cáncer colorrectal metastásico con estabilidad de microsatélites mediante radiómica y biomarcadores circulantes. PI: Iosune Baraibar. Entidad financiadora: Fundación SEOM.
  24. Uso de estreptozotocina en pacientes con tumores neuroendocrinos bien diferenciados: datos de la vida real y comparación con esquemas de quimioterapia basados en temozolomida. PI: Alejandro García. Entidad Financiadora: Grupo Español de Tumores Neuroendorinos y Endocrinos (GETNE). Periodo de Ejecución: 01/01/2024-31/12/2024.
  25. Eficacia de las diferentes secuencias de tratamiento con inhibidores multikinasa en pacientes con carcinoma diferenciado de tiroides en el registro regetne-tiroides. Entidad Financiadora: Grupo Español de Tumores Neuroendorinos y Endocrinos (GETNE). Periodo de Ejecución: 01/01/2024-31/12/2024. PI: Alejandro García

Publicacions

Publicacions científiques més rellevants

  1. Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N Engl J Med. 2025 Jun 26;392(24):2425-2437.
  2. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025 Jul 17;393(3):217-230.
  3. Elez E. Nonoperative Management of dMMR Tumors – A Patient-Centered Approach. N Engl J Med. 2025 Jun 19;392(23):2380-2382.
  4. Elez E, Siena S, Sartore-Bianchi A, Ros J, Ciardello F, Martinelli E, Steeghs N, Huijberts S, Cervantes A, Roselló S, Tejpar S, Wilmsen B, Salazar R, Santos C, de Schaetzen G, Muñoz S, Bernards R, Moreno V, García-Galera E, Alemany R, Gros A, Bardelli A, Arena S, Piris A, Chavarría E, Dienstmann R, Tabernero J. Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. ESMO Open. 2025 Dec;10(12):105892.
  5. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026.
  6. Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul;35(7):643-655.
  7. Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20;42(24):2918-2927.
  8. Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25;15(1):10213.
  9. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53.
  10. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667.
  11. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May;24(5):496-508.
  12. Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023 Jun;34(6):543-552.

Totes les publicacions

  1. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. André, Thierry ; ELEZ FERNANDEZ, MARIA ELENA; Lenz, Heinz-Josef ; Jensen, Lars Henrik ; Touchefeu, Yann ; Van Cutsem, Eric ; Garcia-Carbonero, Rocio ; Tougeron, David ; Mendez, Guillermo Ariel ; Schenker, Michael ; de la Fouchardiere, Christelle ; Limon, Maria Luisa ; Yoshino, Takayuki ; Li, Jin ; Manzano Mozo, Jose Luis ; Dahan, Laetitia ; Tortora, Giampaolo ; Chalabi, Myriam ; Goekkurt, Eray ; Braghiroli, Maria Ignez ; Joshi, Rohit ; Cil, Timucin ; Aubin, Francine ; Cela, Elvis ; Chen, Tian ; Lei, Ming ; Jin, Lixian ; Blum, Steven I ; Lonardi, Sara Lancet. 2025 Feb 1;405(10476):383-395. doi: 10.1016/S0140-6736(24)02848-4.
  2. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. ELEZ FERNANDEZ, MARIA ELENA; Yoshino, Takayuki ; Shen, Lin ; Lonardi, Sara ; Van Cutsem, Eric ; Eng, Cathy ; Kim, Tae Won ; Wasan, Harpreet Singh ; Desai, Jayesh ; Ciardiello, Fortunato ; Yaeger, Rona ; Maughan, Timothy S ; Morris, Van K ; Wu, Christina ; Usari, Tiziana ; Laliberte, Robert ; Dychter, Samuel S ; Zhang, Xiaosong ; TABERNERO CATURLA, JOSEP; Kopetz, Scott ; BREAKWATER Trial Investigators. N Engl J Med. 2025 Jun 26;392(24):2425-2437. doi: 10.1056/NEJMoa2501912. Epub 2025 May 30.
  3. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. André, T ; Shiu, K-K ; Kim, T W ; Jensen, B V ; Jensen, L H ; Punt, C J A ; Smith, D ; Garcia-Carbonero, R ; Alcaide-Garcia, J ; Gibbs, P ; Fouchardiere, C de la ; Rivera, F ; ELEZ FERNANDEZ, MARIA ELENA; Le, D T ; Yoshino, T ; Zuo, Y ; Fogelman, D ; Adelberg, D ; Diaz, L A Jr. Ann Oncol. 2025 Mar;36(3):277-284. doi: 10.1016/j.annonc.2024.11.012. Epub 2024 Dec 2.
  4. The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer. Avolio, Marco ; Leto, Simonetta M ; Sassi, Francesco ; Lupo, Barbara ; Grassi, Elena ; Catalano, Irene ; Zanella, Eugenia R ; Vurchio, Valentina ; Cottino, Francesca ; Tsantoulis, Petros K ; Lazzari, Luca ; Luraghi, Paolo ; Ferri, Martina ; Galimi, Francesco ; Berrino, Enrico ; Bellomo, Sara E ; Viviani, Marco ; Sogari, Alberto ; Mauri, Gianluca ; Tosi, Federica ; Cruciani, Federica ; Sartore-Bianchi, Andrea ; Siena, Salvatore ; Borghi, Felice ; Torri, Valter ; ELEZ FERNANDEZ, MARIA ELENA; TABERNERO CATURLA, JOSEP; Nieva, Maria ; Montagut, Clara ; Tarazona, Noelia ; Cervantes, Andres ; Tejpar, Sabine ; Bardelli, Alberto ; Marchiò, Caterina ; Marsoni, Silvia ; Bertotti, Andrea ; Trusolino, Livio. Cancer Discov. 2026 Feb 6;16(2):270-295. doi: 10.1158/2159-8290.CD-24-0556.
  5. A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1). Andrea Cercek, Jean-Baptiste Bachet, Jaume Capdevila, Naureen Starling, Eric Chen, Lisa Salvatore, Hideaki Bando, Sean O’Donnell, Lauren Harfst, Zsolt Szijgyarto, Volker Heinemann. Clin Colorectal Cancer. 2025 Jun;24(2):325-330. doi: 10.1016/j.clcc.2025.02.003. Epub 2025 Feb 21.
  6. Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors. Nasca, Vincenzo ; Zhao, Joseph ; ROS MONTAÑA, JAVIER; Lonardi, Sara ; Zwart, Koen ; Cohen, Romain ; Fakih, Marwan ; Jayachandran, Priya ; Roodhart, Jeanine M. L. ; Derksen, Jeroen ; Intini, Rossana ; Bergamo, Francesca ; Mazzoli, Giacomo ; Ghelardi, Filippo ; LIGERO HERNANDEZ, MARTA; Jonnagaddala, Jitendra ; Hawkins, Nicholas ; Ward, Robyn L. ; Wankhede, Durgesh ; Brenner, Hermann ; Hoffmeister, Michael ; Vitellaro, Marco ; Salvatore, Lisa ; Gallois, Claire ; Laurent-Puig, Pierre ; Cremolini, Chiara ; Overman, Michael J. ; Taieb, Julien ; Tougeron, David ; Andre, Thierry ; Kather, Jakob Nikolas ; Sundar, Raghav ; Carmona, Javier ; ELEZ FERNANDEZ, MARIA ELENA; Koopman, Miriam ; Pietrantonio, Filippo. J Immunother Cancer.2025 Feb 10;13(2):e010598. doi: 10.1136/jitc-2024-010598.
  7. Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors. Taieb, Julien ; Ambrosini, Margherita ; Alouani, Emily ; Lonardi, Sara ; Sinicrope, Frank A ; Decraecker, Marie ; Boileve, Alice ; Hafliger, Emilie ; Mazard, Thibault ; Pernot, Simon ; Parent, Pauline ; ROS MONTAÑA, JAVIER; Overman, Michael J ; Jayachandran, Priya ; Nasca, Vincenzo ; Salvatore, Lisa ; Guimbaud, Rosine ; Cremolini, Chiara ; Tougeron, David ; Pietrantonio, Filippo. J Immunother Cancer.2025 Jan 4;13(1):e010424. doi: 10.1136/jitc-2024-010424.
  8. Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Gallois, Claire ; Ambrosini, Margherita ; Lonardi, Sara ; Alouani, Emily ; Guimbaud, Rosine ; Overman, Michael J ; Sinicrope, Frank ; Mazard, Thibault ; Decraecker, Marie ; ROS MONTAÑA, JAVIER; ELEZ FERNANDEZ, MARIA ELENA; Pernot, Simon ; Cremolini, Chiara ; Boilève, Alice ; Parent, Pauline ; Jayachandran, Priya ; Dutherage, Marie ; Mercier, Mathilde ; Flecchia, Clémence ; Fakih, Marwan ; Sclafani, Francesco ; Pietrantonio, Filippo ; Taieb, Julien ; Tougeron, David. Eur J Cancer.2025 Sep 9:227:115645. doi: 10.1016/j.ejca.2025.115645. Epub 2025 Jul 12.
  9. Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. Taieb, Julien; Modest, Dominik P; Fakih, Marwan; Ciardiello, Fortunato; Van Cutsem, Eric; ELEZ FERNANDEZ, MARIA ELENA; Gravalos, Cristina; Bragagnoli, Arinilda Campos; Barboux, Valentine; Roby, Lucas; Amellal, Nadia; Prager, Gerald W. Eur J Cancer. 2025 Sep 9:227:115644. doi: 10.1016/j.ejca.2025.115644. Epub 2025 Jul 12.
  10. Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. Sobrero, Alberto ; Dasari, Arvind ; Aquino, Jeneth ; Lonardi, Sara ; Garcia-Carbonero, Rocio ; ELEZ FERNANDEZ, MARIA ELENA; Yoshino, Takayuki ; Yao, James ; Garcia-Alfonso, Pilar ; Kocsis, Judit ; Gracian, Antonio Cubillo ; Sartore-Bianchi, Andrea ; Satoh, Taroh ; Randrian, Violaine ; Tomasek, Jiri ; Chong, Geoff ; Price, Timothy ; Yu, Ziji ; Geiger, Ashley ; Chen, Lucy ; Yang, Zhao ; Schelman, William R ; Kania, Marek ; TABERNERO CATURLA, JOSEP; Eng, Cathy. Eur J Cancer. 2025 Mar 11:218:115268. doi: 10.1016/j.ejca.2025.115268. Epub 2025 Jan 29
  11. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2. Stintzing, S ; TABERNERO CATURLA, JOSEP; Satoh, T ; Dasari, A ; Lonardi, S ; Eng, C ; Garcia-Carbonero, R ; ELEZ FERNANDEZ, MARIA ELENA; Yoshino, T ; Sobrero, A F ; Yao, J C ; Kasper, S ; Arnold, D ; Basic, E ; Granold, M ; Petschulies, M ; Wu, L ; Chung, Y-C ; Chen, L ; Yang, Z ; Van Cutsem, E. ESMO Open. 2025 Mar;10(3):104297. doi: 10.1016/j.esmoop.2025.104297. Epub 2025 Feb 21.
  12. Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. ELEZ FERNANDEZ, MARIA ELENA; Siena, S ; Sartore-Bianchi, A ; ROS MONTAÑA, JAVIER; Ciardello, F; Martinelli, E ; Steeghs, N; Huijberts, S; Cervantes, A; Roselló, S; Tejpar, S; Wilmsen, B; Salazar, R; Santos, C; de Schaetzen, G; MUÑOZ TABERNERO, SUSANA; Bernards, R; Moreno, V; García-Galera, E; Alemany, R; GROS VIDAL, ALENA; Bardelli, A; Arena, S; PIRIS GIMENEZ, ALEJANDRO; CHAVARRIA MIRAS, ELENA; DIENSTMANN, RODRIGO; TABERNERO CATURLA, JOSEP. ESMO Open.2025 Dec;10(12):105892. doi: 10.1016/j.esmoop.2025.105892. Epub 2025 Dec 2.
  13. Differentiating low tumor burden from oligometastatic disease in colorectal cancer: a call for individualized therapeutic approaches. de Grandis, M C ; BARAIBAR ARGOTA, IOSUNE; Prior, O ; Balaguer-Montero, M ; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; RODRIGUEZ CASTELLS, MARTA; TABERNERO CATURLA, JOSEP; Lonardi, S ; PEREZ LOPEZ, RAQUEL; ELEZ FERNANDEZ, MARIA ELENA. ESMO Open.2025 Aug;10(8):105520. doi: 10.1016/j.esmoop.2025.105520. Epub 2025 Aug 12.
  14. Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study. Martelli, V ; Vidal, J ; Gibert, J ; Fernández-Rodríguez, M C ; Linares, J ; García-Alfonso, P ; Páez, D ; Alonso, V ; Gomez-España, M A ; Guix, M ; Santos, C ; Duran, G ; ELEZ FERNANDEZ, MARIA ELENA; Garcia-Carbonero, R ; Ferreiro, R ; Pineda, E ; Sastre, J ; Cano, M T ; Manzano, J L ; Losa, F ; Aranda, E ; Rivera, F ; Sibilio, A ; DE ALMEIDA TOLEDO, RODRIGO; TABERNERO CATURLA, JOSEP; Salazar, R ; Bellosillo, B ; Montagut, C ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). ESMO Open. 2025 Sep;10(9):105760. doi: 10.1016/j.esmoop.2025.105760. Epub 2025 Sep 3.
  15. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. Eng, Cathy ; Dasari, Arvind ; Lonardi, Sara ; Garcia-Carbonero, Rocio ; ELEZ FERNANDEZ, MARIA ELENA; Yoshino, Takayuki ; Sobrero, Alberto ; Yao, James ; Garcia-Alfonso, Pilar ; Kocsis, Judit ; Gracian, Antonio Cubillo ; Sartore-Bianchi, Andrea ; Satoh, Taroh ; Randrian, Violaine ; Tomasek, Jiri ; Chong, Geoff ; Yang, Zhao ; Guevara, Ferdinand ; Schelman, William ; Pallai, Rajash ; TABERNERO CATURLA, JOSEP. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.
  16. First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancer. Nasca, Vincenzo ; Tine, Gabriele ; Taieb, Julien ; Lonardi, Sara ; Boursi, Ben ; Margalit, Ofer ; Salvatore, Lisa ; Cohen, Romain ; ROS MONTAÑA, JAVIER; Ambrosini, Margherita ; Zwart, Koen ; Roodhart, Jeanine ; Jayachandran, Priya ; Overman, Michael J. ; ELEZ FERNANDEZ, MARIA ELENA; Cremolini, Chiara ; Tougeron, David ; Koopman, Miriam ; Andre, Thierry ; Miceli, Rosalba ; Pietrantonio, Filippo. Oncologist. 2025 Sep 1;30(9):oyaf255. doi: 10.1093/oncolo/oyaf255.
  17. Fertility preservation practices and gastrointestinal oncologist in Europe: a pan-European study. Ben-Aharon, Irit ; Goshen-Lago, Tal ; Puccini, Alberto ; Alsina, Maria ; Arnold, Dirk ; Von-Larhoven, Hanneke ; Elme, Anneli ; Buffart, Tineke ; Fokter-Dovnik, Nina ; Sokop, Tomas ; Obermanova, Radka ; Lordick, Florian ; Papamichael, Demetris ; Sclafani, Francesco ; ELEZ FERNANDEZ, MARIA ELENA; Taieb, Julien. Oncologist. 2025 Nov 11;30(11):oyaf350. doi: 10.1093/oncolo/oyaf350.
  18. A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC). Aroldi, Francesca ; ELEZ FERNANDEZ, MARIA ELENA; André, Thierry ; Perkins, Geraldine ; Prenen, Hans ; Popovici, Vlad ; Gallagher, Peter ; Houlden, Jennifer ; Collins, Linda ; Roberts, Corran ; Rolfo, Christian ; Di Nicolantonio, Federica ; Grayson, Margaret ; Boyd, Ruth ; Bettens, Karolien ; Delfavero, Jurgen ; Coyle, Victoria ; Lawler, Mark ; Khawaja, Hajrah ; Laurent-Puig, Pierre ; Salto-Tellez, Manuel ; Maughan, Tim S ; TABERNERO CATURLA, JOSEP; Adams, Richard ; Jones, Robert ; Hennessy, Bryan T ; Bardelli, Alberto ; Peeters, Marc ; Middleton, Mark R ; Wilson, Richard H ; Van Schaeybroeck, Sandra ; MErCuRIC Trial Consortium. BMC Cancer.2025 Apr 10;25(1):658. doi: 10.1186/s12885-025-14068-1.
  19. BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancer. Kopetz, Scott ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA. Future Oncol.2025 Dec;21(28):3585-3588. doi: 10.1080/14796694.2025.2579882. Epub 2025 Nov 13.
  20. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Soler, Gemma ; Grávalos, Cristina ; Rivera, Fernando ; Safont, María José ; Virgili, Anna C ; Valladares-Ayerbes, Manuel ; Ferreiro-Monteagudo, Reyes ; Ortiz-Morales, María José ; Polo-Marques, Eduardo ; Kornusova-Bersheva, Irina ; Soustre, Elsa ; Yao, Weiyu ; ELEZ FERNANDEZ, MARIA ELENA. Clin Transl Oncol.2025 Nov;27(11):4203-4213. doi: 10.1007/s12094-025-03907-z. Epub 2025 May 8.
  21. Gender and sex differences in colorectal cancer screening, diagnosis and treatment. González-Flores, Encarnación ; Garcia-Carbonero, Rocio ; ELEZ FERNANDEZ, MARIA ELENA; Redondo-Cerezo, Eduardo ; Safont, María José ; Vera García, Ruth. Clin Transl Oncol.2025 Jul;27(7):2825-2837. doi: 10.1007/s12094-024-03801-0. Epub 2025 Jan 17.
  22. Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus. García-Alfonso, Pilar ; Alcaide-Garcia, Julia ; Aranda Aguilar, Enrique ; ELEZ FERNANDEZ, MARIA ELENA; Fernández Montes, Ana ; García Escobar, Ignacio ; Grávalos, Cristina ; Matos García, Ignacio ; Montagut Viladot, Clara ; Santos Vivas, Cristina ; Sastre, Javier ; Tarazona, Noelia ; Jimenez-Fonseca, Paula. Clin Transl Oncol.2026 Feb;28(2):617-624. doi: 10.1007/s12094-025-03986-y. Epub 2025 Aug 11.
  23. Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations. ROS MONTAÑA, JAVIER; NAVARRO GARCES, VICTOR; VILLACAMPA JAVIERRE, GUILLERMO; BARAIBAR ARGOTA, IOSUNE; SALVA BALLABRERA, FRANCESC; RODRIGUEZ CASTELLS, MARTA; Vaghi, C. ; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaraz, A. ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA; DIENSTMANN, RODRIGO. ESMO Gastrointest Oncol.2025 Aug 18:9:100225. doi: 10.1016/j.esmogo.2025.100225. eCollection 2025 Sep.
  24. Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients. SALVA BALLABRERA, FRANCESC; Catani, G. ; Saoudi, N. ; BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; RODRIGUEZ CASTELLS, MARTA; de Torres, C. Salva ; Alcaraz, A. ; GARCIA RODRIGUEZ, ARIADNA MARIA; COMAS NAVARRO, RAQUEL; RUIZ PACE, FIORELLA DAFNE; REZQALLAH ARON, ALEJANDRA; DIENSTMANN, RODRIGO; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA. ESMO Gastrointest Oncol.2025 Aug 26:9:100230. doi: 10.1016/j.esmogo.2025.100230. eCollection 2025 Sep.
  25. Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases?the PURPLE trial. Kasper, S. ; ELEZ FERNANDEZ, MARIA ELENA; Neumann, U. ; Lang, S. ; Trampe, A. -K. ; SALVA BALLABRERA, FRANCESC; Dopazo, C. ; Virchow, I. ; Hartmann, S. ; Herrmann, K. ; TABERNERO CATURLA, JOSEP; Westendorf, A. ; Schuler, M. ; Schramm, A. ESMO Gastrointest Oncol.2025 Sep 1:9:100226. doi: 10.1016/j.esmogo.2025.100226. eCollection 2025 Sep.
  26. European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’. Folprecht, G. ; Morfouace, M. ; Collienne, M. ; Salazar, R. ; Stein, A. ; ELEZ FERNANDEZ, MARIA ELENA; Wagner, A. D. ; Arnold, D. ; Kohne, C. H. ; Ducreux, M. ; Lordick, F. ; Borelli, B. ; Stevovic, A. ; Gorlia, T. ; Fontana, E. ; Aust, D. ; Golfinopoulos, V. ; Moehler, M. ; Tejpar, S. ESMO Gastrointest Oncol.2025 Apr 9:8:100168. doi: 10.1016/j.esmogo.2025.100168. eCollection 2025 Jun.
  27. Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil. Prager, G. W. ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, M. ; Ciardiello, F. ; Van Cutsem, E. ; Roby, L. ; Yao, W. ; Choucair, E. ; Taieb, J. ESMO Gastrointest Oncol.2025 Dec doi: 10.1016/j.esmogo.2025.100234 eCollection 2025 Sept.
  28. Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study. Garcia-Carbonero, R. ; ELEZ FERNANDEZ, MARIA ELENA; Garcia-Alfonso, P. ; Gracian, A. Cubillo ; Lopez, R. Lopez ; Jimenez-Fonseca, P. ; Miron, M. L. Limon ; Dasari, A. ; Lonardi, S. ; Zhu, H. ; Chen, L. ; Yang, Z. ; Schelman, W. R. ; TABERNERO CATURLA, JOSEP. ESMO Gastrointest Oncol. 2025 Jul 15:9:100205. doi: 10.1016/j.esmogo.2025.100205. eCollection 2025 Sep.
  29. Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis. Calle, Candela ; ELEZ FERNANDEZ, MARIA ELENA; Manzano, Jose Luis ; Moreno-Martinez, Maria-Estela ; Pericay, Carles ; Graefenhain, Ruth ; Ariznavarreta, Asis ; Lizan, Luis. J Pharm Policy Pract. 2025 Oct 13;18(1):2567970. doi: 10.1080/20523211.2025.2567970. eCollection 2025.
  30. Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer. Renner, Florian; Eckmann, Jan; Handl, Cornelia; Wichmann, Jürgen; Schnetzler, Gabriel; Kratochwil, Nicole A; Keshelava, Nino; ROS MONTAÑA, JAVIER; ELEZ FERNANDEZ, MARIA ELENA; VERGES CAPDEVILA, RAMONA; CHICOTE RAMOS, IRENE; MARTINEZ-QUINTANILLA MARTINEZ, JORDI; GARCIA PALMER, HECTOR; Pettazzoni, Piergiorgio. Mol Cancer Ther.2025 Dec 4. doi: 10.1158/1535-7163.MCT-25-0562. Online ahead of print.
  31. A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1). Cercek, Andrea ; Bachet, Jean-Baptiste; CAPDEVILA CASTILLON, JAUME; Starling, Naureen; Chen, Eri; Salvatore, Lisa; Bando, Hideaki; O’Donnell, Sean; Harfst, Lauren; Szijgyarto, Zsolt; Heinemann, Volker. Clin Colorectal Cancer.2025 Jun;24(2):325-330. doi: 10.1016/j.clcc.2025.02.003. Epub 2025 Feb 21.
  32. A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Balaguer-Montero M, Marcos Morales A, Ligero M, Zatse C, Leiva D, Atlagich LM, Staikoglou N, Viaplana C, Monreal C, Mateo J, Hernando J, García-Álvarez A, Salvà F, Capdevila J, Elez E, Dienstmann R, Garralda E, Perez-Lopez R. Cell Rep Med. 2025 Apr 15;6(4):102032. doi: 10.1016/j.xcrm.2025.102032. Epub 2025 Mar 20.
  33. Short- and long-term mortality in critically ill patients with solid cancer. The Vall d’Hebron Intensive Care Unit-Vall d’Hebron Institute of Oncology Cohort: a retrospective study. Díaz-Lagares C, García-Roche A, Pacheco A, Ros J, Plata-Menchaca EP, Albasanz A, Pérez D, Saoudi N, Ruiz-Camps I, Élez E, Ferrer R. Med Intensiva (Engl Ed). 2025 Nov;49(11):502176. doi: 10.1016/j.medine.2025.502176. Epub 2025 Mar 18.
  34. Detecting Cancer Early with Ultrasensitive Multimodal Liquid Biopsy. Crisafulli G, Saoudi Gonzalez N, Patelli G, Bardelli A. Cancer Discov. 2025 Sep 4;15(9):1774-1776. doi: 10.1158/2159-8290.CD-25-1025.
  35. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Pacheco-Barcia V, Obispo B, Tomas E, Salva de Torres C, Quintanar T, Paez D, Leon-Mateos L, Cancio H, Cortegoso A, Anido U, Quilez A, Tarazona N, Jimenez-Labaig P, Sanchez-Martinez DA, Sesma Goni A, Fernandez-Montes A, Felip E, Rodriguez C, Elez E. Clin Transl Oncol. 2025 Dec 23. doi: 10.1007/s12094-025-04171-x.
  36. Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis. Moreno-Cárdenas AB, Ros J, et al. Ann Rheum Dis. 2025 Nov 24:S0003-4967(25)04457-7. doi: 10.1016/j.ard.2025.10.018. Epub ahead of print.
  37. Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort. E. TERÁN et al. ESMO Open. 2026 Jan 27;11(2):106053. doi: 10.1016/j.esmoop.2025.106053. Epub ahead of print.
  38. HER2-Low vs. HER2-Null in Advanced Gastric Cancer: Real-World Evidence from a Multicenter Cohort. B. Bahar, E. TERÁN et al. Accepted. Jamma Network Open.
  39. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, TABERNERO J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119.
  40. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, TABERNERO J; MATTERHORN Investigators. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701.
  41. Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. Shitara K, Lorenzen S, Li J, Bai Y, Fernández MG, Aguilar M, Shoji H, Reyes-Cosmelli F, Peña YR, Corrales L, Wyrwicz L, EYZAGUIRRE DA, Pan Y, Ryu MH, Cohen DJ, Wainberg ZA, Ku G, TABERNERO J, Van Cutsem E, Qin SK, Oh DY, Xu J, Liang LW, Bordia S, Bhagia P, Rha SY; LEAP-015 Investigators. J Clin Oncol. 2025 Aug;43(22):2502-2514. doi: 10.1200/JCO-25-00748.
  42. Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers. Hurvitz S, Simonelli M, Yarza R, Berz D, Kitano S, Del Conte G, ACOSTA EYZAGUIRRE D, Doger de Speville Uribe BG, Maier D, Erzen D, Aykut Yazgili S, Curigliano G, Deng T, Yan M, Zhang Q, Wang X, Nakayama I, Shitara K. Future Oncol. 2025 Nov;21(26):3385-3393. doi: 10.1080/14796694.2025.2569553.
  43. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis. Mateos L, Jiménez-Fonseca P, Gallego J, Lecumberri A, Custodio A, Martínez de Castro E, Hernández San Gil R, Fernández Montes A, Limón ML, Vidal-Tocino R, Cano JM, López Robles J, Gil M, ACOSTA EYZAGUIRRE D, Marín Zafra G, Mérida-García AJ, Francisco Fernández A, Ribera Fernández P, Hierro C, Riesco MC, García Araque M, Ruiz Martín M, Pimentel P, Visa L, Cerdá P, Granja M, Rupérez Blanco AB, Gutiérrez L, Carmona-Bayonas A. Br J Cancer. 2026 Feb;134(3):414-427. doi: 10.1038/s41416-025-03264-2.
  44. Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy. Zhao X, Hao Q, Alsina M, ACOSTA D, Castet F, TERÁN E, CANO KV, Saurí T, Macías I, Yoshikawa T, Castro S, Shoji H, Lordick F, Shen Z, Tian TV, Macarulla T. Cancer Treat Rev. 2025 Dec;141:103041. doi: 10.1016/j.ctrv.2025.103041.
  45. Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study. Niger M, Rimini M, Castet F, Melzer A, Rizzato MD, Pressiani T, Lavacchi D, Aprile G, Angela T, Saladino T, Silvia N, Cito P, Pastorino A, TERÁN-BRAGE E, Sciortino C, Camera S, Pircher C, Persano M, Mazzaferro V, Foti S, VEGA KS, Ettrich TJ, Antonuzzo L, Rimassa L, Lonardi S, Perkhofer L, Macarulla T, Pietrantonio F, Casadei-Gardini A. Liver Int. 2025 Sep;45(9):e70295. doi: 10.1111/liv.70295
  46. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
  47. Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul;35(7):643-655. doi: 10.1016/j.annonc.2024.03.009.
  48. Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20;42(24):2918-2927. doi: 10.1200/JCO.23.02736.
  49. Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Erratum in: Nat Commun. 2025 Jan 15;16(1):704. doi: 10.1038/s41467-025-56170-9.
  50. Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409.
  51. Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clin Cancer Res. 2024 Jan 17;30(2):436-443. doi: 10.1158/1078-0432.CCR-23-1379.
  52. Martínez-Quintanilla J, Cabot D, Sabia D, Arqués O; PMPnet Group; Vergés J, Chicote I, Bijelic L; PMPnet Group; Cabellos L, Alcántara AM, Ramos I, Barrios P, Crusellas O, Palacio LM; PMPnet Group; Cámara JA, Barriuso J; PMPnet Group; Jiménez JJ, Muñoz-Torres P, Nonell L, Flores R, Médico E, Guaglio M; PMPnet Group; Ros J, Élez E, Tabernero J, Aziz O, Deraco M, Palmer HG; PMPnet Group; PMPnet Group. Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. Clin Cancer Res. 2024 Sep 13;30(18):4082-4099. doi: 10.1158/1078-0432.CCR-23-4072.
  53. Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer. EBioMedicine. 2024 Oct;108:105352. doi: 10.1016/j.ebiom.2024.105352.
  54. Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, Pietrantonio F, Lonardi S, Gallois C, Taieb J. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290.
  55. Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458.
  56. García-Alfonso P, Elez E, Soto-Alsar J, Páez D, Fernández-Montes A, Graña B, Salud A, Yubero A, Gómez-España MA, Macías I, Quintero G, López-López C, Fernández-Rodríguez T, Grávalos C, González-Flores E, Guix M, García Paredes B, Reina JJ, Rodríguez Mowbray JR, Sastre J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 2024 Dec;9(12):103986. doi: 10.1016/j.esmoop.2024.103986.
  57. Segal NH, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, Hollebecque A, Reilley MJ, Elez E, Cosaert J, Cain J, Soo-Hoo Y, Hewson N, Cooper ZA, Kumar R, Tabernero J. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. Br J Cancer. 2024 Oct;131(6):1005-1013. doi: 10.1038/s41416-024-02796-3.
  58. Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B, Alcasid A, Zhang X, Van Cutsem E. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. BMC Cancer. 2024 Apr 11;24(1):446. doi: 10.1186/s12885-024-12153-5.
  59. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Élez E, Wyrwicz L, Stroyakovskiy D, Liposits G, Bondarenko I, Modest DP, Amellal N, Tabernero J; SUNLIGHT Investigators. Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer. Future Oncol. 2024;20(36):2823-2832. doi: 10.1080/14796694.2024.2366100.
  60. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249.
  61. García-Alfonso P, Vera R, Aranda E, Élez E, Rivera F. Delphi consensus for the third-line treatment of metastatic colorectal cancer. Clin Transl Oncol. 2024 Jun;26(6):1429-1437. doi: 10.1007/s12094-023-03369-1.
  62. Salvà F, Saoudi N, Rodríguez M, Baraibar I, Ros J, García A, Tabernero J, Elez E. Determinants of Metastatic Colorectal Cancer With Permanent Liver- Limited Disease. Clin Colorectal Cancer. 2024 Sep;23(3):207-214. doi: 10.1016/j.clcc.2024.05.010.
  63. Ros J, Vaghi C, Baraibar I, Saoudi González N, Rodríguez-Castells M, García A, Alcaraz A, Salva F, Tabernero J, Elez E. Targeting KRASG12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. Int J Mol Sci. 2024 Mar 14;25(6):3304. doi: 10.3390/ijms25063304.
  64. Salva de Torres C, Baraibar I, Saoudi González N, Ros J, Salva F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer. Int J Mol Sci. 2024 Jun 26;25(13):6967. doi: 10.3390/ijms25136967.
  65. Saoudi González N, Ros J, Baraibar I, Salvà F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers (Basel). 2024 Jan 18;16(2):412. doi: 10.3390/cancers16020412.
  66. González NS, Marchese PV, Baraibar I, Ros J, Salvà F, Rodríguez M, Salvà C, Vaghi C, Alcaraz A, García A, Tabernero J, Élez E. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. Expert Opin Investig Drugs. 2024 Jun;33(6):613-625. doi: 10.1080/13543784.2024.2349287.
  67. Contreras-Toledo D, Jiménez-Fonseca P, López CL, Montes AF, López Muñoz AM, Vázquez Rivera F, Alonso V, Alcaide J, Salvà F, Covela Rúa M, Guillot M, Martín Carnicero A, Jimeno Mate R, Cameselle García S, Asensio Martínez E, González Astorga B, Fernandez-Diaz AB, González Villaroel P, Virgili Manrique AC, Melián Sosa M, Alonso B, Cousillas Castiñeiras A, Castañón López C, Aparicio J, Carmona-Bayonas A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist? Br J Cancer. 2024 Mar;130(5):777-787. doi: 10.1038/s41416-023-02563-w.
  68. Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, Rossi G, Vanni I, Longo L, Tagliamento M, Zullo L, Dal Bello MG, Dellepiane C, Alama A, Rijavec E, Ludovini V, Barletta G, Passiglia F, Metro G, Baglivo S, Chiari R, Rivoltini L, Biello F, Baraibar I, Gil-Bazo I, Novello S, Grossi F, Coco S. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8.
  69. Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment. Biomed Pharmacother. 2024 Jul;176:116857. doi: 10.1016/j.biopha.2024.116857.
  70. Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dienstmann R, Tabernero J, Vivancos A, Elez E. Corrigendum to «Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments»: [Annals of Oncology 34 (2023) 543-552]. Ann Oncol. 2024 Oct;35(10):922. doi: 10.1016/j.annonc.2023.07.010. Epub 2024 Aug 12. Erratum for: Ann Oncol. 2023 Jun;34(6):543-552.
  71. García-Alfonso P, Jimenez-Fonseca P, Soto-Alsar J, Baraibar I, Santos C, La Casta A, Ghanem I, Pulido Cortijo G, Mariño Méndez A, Pazo-Cid R, Vera R, Melián M, Alcaide J, Graña B, Páez D, Gallego I, Lobo M, Borregón M, Fernández Montes A, Martínez de Castro E, Carmona-Bayonas A, Aranda E. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. Oncologist. 2024 Nov 16:oyae300. doi: 10.1093/oncolo/oyae300.
  72. Ros J, Ucha JM, Garcia-Galea E, Gomez P, Martini G, Balconi F, Comas R, Alonso V, Rodriguez M, Baraibar I, Salva F, Saoudi N, Alcaraz A, Garcia A, Tabernero J, Elez E. Real-World Data of Patients with BRAFV600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil. Cancers (Basel). 2024 Dec 12;16(24):4140. doi: 10.3390/cancers16244140.
  74. Fruquintinib versus placebo in patients with refractory metastatic colorectal  cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase  3 study..Dasari, Arvind ; Lonardi, Sara ; Garcia-Carbonero, Rocio ; ELEZ FERNANDEZ, MARIA ELENA; Yoshino, Takayuki ; Sobrero, Alberto ; Yao, James ; García-Alfonso, Pilar ; Kocsis, Judit ; Cubillo Gracian, Antonio ; Sartore-Bianchi, Andrea ; Satoh, Taroh ; Randrian, Violaine ; Tomasek, Jiri ; Chong, Geoff ; Paulson, Andrew Scott ; Masuishi, Toshiki ; Jones, Jeremy ; Csoszi, Tibor ; Cremolini, Chiara ; Ghiringhelli, Francois ; Shergill, Ardaman ; Hochster, Howard S ; Krauss, John ; Bassam, Ali ; Ducreux, Michel ; Elme, Anneli ; Faugeras, Laurence ; Kasper, Stefan ; Van Cutsem, Eric ; Arnold, Dirk ; Nanda, Shivani ; Yang, Zhao ; Schelman, William R ; Kania, Marek ; TABERNERO CATURLA, JOSEP; Eng, Cathy ; FRESCO-2 Study Investigators.LANCET.1.1.168,9.13.10.1016/S0140-6736(23)00772-9
  75. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer..Hadoux, Julien ; Elisei, Rossella ; Brose, Marcia S ; Hoff, Ana O ; Robinson, Bruce G ; Gao, Ming ; Jarzab, Barbara ; Isaev, Pavel ; Kopeckova, Katerina ; Wadsley, Jonathan ; Führer, Dagmar ; Keam, Bhumsuk ; Bardet, Stéphane ; Sherman, Eric J ; Tahara, Makoto ; Hu, Mimi I ; Singh, Ravinder ; Lin, Yan ; Soldatenkova, Victoria ; Wright, Jennifer ; Lin, Boris ; Maeda, Patricia ; CAPDEVILA CASTILLON, JAUME; Wirth, Lori J ; LIBRETTO-531 Trial Investigators.NEW ENGLAND JOURNAL OF MEDICINE.1.1.158,5.7.10.1056/NEJMoa2309719
  76. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal  Cancer..Prager, Gerald W ; Taieb, Julien ; Fakih, Marwan ; Ciardiello, Fortunato ; Van Cutsem, Eric ; ELEZ FERNANDEZ, MARIA ELENA; Cruz, Felipe M ; Wyrwicz, Lucjan ; Stroyakovskiy, Daniil ; Pápai, Zsuzsanna ; Poureau, Pierre-Guillaume ; Liposits, Gabor ; Cremolini, Chiara ; Bondarenko, Igor ; Modest, Dominik P ; Benhadji, Karim A ; Amellal, Nadia ; Leger, Catherine ; Vidot, Loïck ; TABERNERO CATURLA, JOSEP; SUNLIGHT Investigators ; Amann, Arno ; Gerger, Armin ; Greil, Richard ; Gruenberger, Birgit ; Popper, Ulrich ; Prager, Gerald ; Winder, Thomas ; Hendrickx, Koen ; Houbiers, Ghislain ; Lybaert, Willem ; Peeters, Marc ; Van Custem, Eric ; Abdalla, Káthia Cristina ; Campos Bragagnoli, Arinilda ; Carmagani Pestana, Roberto ; Cruz, Felipe José Silva Melo ; Spina Donadio, Mauro Daniel ; Fernandes, Gustavo Dos Santos ; Moniz, Camila Motta Venchiarutti ; Liposits, Gabor Istvan ; Olesen, Rene ; Petersen, Lone Nørgård ; Pfeiffer, Per ; Borg, Christophe ; Boussion, Helene ; Galais, Marie-Pierre ; Poureau, Pierre-Guillaume ; Taieb, Julien ; Tougeron, David ; Heinemann, Volker ; Kisro, Jens ; Modest, Dominik Paul ; Schwaner, Ingo ; Arkosy, Péter ; Bodoky, György ; Csejtei, András ; Csöszi, Tibor ; Horvath, Zsolt ; Nagy, Zoltan ; Olah, Judith ; Pápai, Zsuzsanna ; Sipöcz, István ; Avallone, Antonio ; Banzi, Maria ; Bilancia, Domenico ; Ciardiello, Fortunato ; Cremolini, Chiara ; Lonardi, Sara ; Maiello, Evaristo ; Personeni, Nicola ; Scartozzi, Mario ; Duchnowska, Renata ; Itrych, Bartosz ; Karaszewska, Boguslawa ; Radecka, Barbara ; Rogowski, Wojciech ; Wyrwicz, Lucjan ; Wysocki, Piotr ; Fedyanin, Mikhail ; Kirtbaya, Dmitry ; Kislov, Nikolay ; Kopp, Mikhail ; Lebedeva, Ludmila ; Ledin, Evgeny ; Makarova, Yulia ; Moiseenko, Fedor ; Orlova, Rashida ; Radyukova, Irina ; Semiglazova, Tatiana ; Stroyakovskyi, Daniil ; Tjulandin, Sergei A ; ELEZ FERNANDEZ, MARIA ELENA; Ferreiro-Monteagudo, Reyes ; Grávalos-Castro, Cristina ; Polo-Marqués, Eduardo ; Pachón Olmos, Vanessa ; Ortiz-Morales, María José ; Rivera, Fernando ; Safont, María José ; Soler, Gemma ; TABERNERO CATURLA, JOSEP; Valladares Ayerbes, Manuel ; Virgili Manrique, Anna C ; Bondarekno, Igor ; Kolachko, Iryna ; Krulko, Stepan ; Ostapenko, Yuriy ; Paramonov, Viktor ; Ponomarova, Olga ; Ryspayeva, Dinara ; Shevnia, Serhii ; Shparyk, Yaroslav ; Bekaii-Saab, Tanios S ; Birhiray, Ruemu E ; Burhani, Nafisa ; Cruz-Correa, Marcia ; Cusnir, Mike ; Desai, Pratibha ; Fakih, Marwan G ; Hall, Ryan ; Jin, Zhaohui ; Jones, Jeremy C ; Lu, Jonathan ; Natarajan, Nagendra ; Shahinian, Haroutioun.NEW ENGLAND JOURNAL OF MEDICINE.1.1.158,5. .10.1056/NEJMoa2214963
  77. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR  trial..Subbiah, Vivek ; Kreitman, Robert J ; Wainberg, Zev A ; Gazzah, Anas ; Lassen, Ulrik ; Stein, Alexander ; Wen, Patrick Y ; Dietrich, Sascha ; de Jonge, Maja J A ; Blay, Jean-Yves ; Italiano, Antoine ; Yonemori, Kan ; Cho, Daniel C ; de Vos, Filip Y F L ; Moreau, Philippe ; ELEZ FERNANDEZ, MARIA ELENA; Schellens, Jan H M ; Zielinski, Christoph C ; Redhu, Suman ; Boran, Aislyn ; Passos, Vanessa Q ; Ilankumaran, Palanichamy ; Bang, Yung-Jue.NATURE MEDICINE.1.1.82,9.30.10.1038/s41591-023-02321-8
  78. Seeking therapeutic synergy in BRAF mutant colorectal cancer..ELEZ FERNANDEZ, MARIA ELENA; ROS MONTAÑA, JAVIER; TABERNERO CATURLA, JOSEP.NATURE MEDICINE.1.1.82,9.4.10.1038/s41591-022-02192-5
  79. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine  tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study..Nesti, Cédric ; Bräutigam, Konstantin ; Benavent, Marta ; Bernal, Laura ; Boharoon, Hessa ; Botling, Johan ; Bouroumeau, Antonin ; Brcic, Iva ; Brunner, Maximilian ; Cadiot, Guillaume ; Camara, Maria ; Christ, Emanuel ; Clerici, Thomas ; Clift, Ashley K ; Clouston, Hamish ; Cobianchi, Lorenzo ; Cwikla, Jaroslaw B ; Daskalakis, Kosmas ; Frilling, Andrea ; Garcia-Carbonero, Rocio ; Grozinsky-Glasberg, Simona ; HERNANDO CUBERO, JORGE; Hervieu, Valérie ; Hofland, Johannes ; Holmager, Pernille ; Inzani, Frediano ; Jann, Henning ; Jimenez-Fonseca, Paula ; Kaçmaz, Enes ; Kaemmerer, Daniel ; Kaltsas, Gregory ; Klimacek, Branislav ; Knigge, Ulrich ; Kolasinska-Cwikla, Agnieszka ; Kolb, Walter ; Kos-Kudla, Beata ; Kunze, Catarina Alisa ; Landolfi, Stefania ; Rosa, Stefano La ; López, Carlos López ; Lorenz, Kerstin ; Matter, Maurice ; Mazal, Peter ; Mestre-Alagarda, Claudia ; Del Burgo, Patricia Morales ; van Dijkum, Els J M Nieveen ; Oleinikov, Kira ; Orci, Lorenzo A ; Panzuto, Francesco ; Pavel, Marianne ; Perrier, Marine ; Reims, Henrik Mikael ; Rindi, Guido ; Rinke, Anja ; Rinzivillo, Maria ; Sagaert, Xavier ; Satiroglu, Ilker ; Selberherr, Andreas ; Siebenhüner, Alexander R ; Tesselaar, Margot E T ; Thalhammer, Michael J ; Thiis-Evensen, Espen ; Toumpanakis, Christos ; Vandamme, Timon ; van den Berg, José G ; Vanoli, Alessandro ; van Velthuysen, Marie-Louise F ; Verslype, Chris ; Vorburger, Stephan A ; Lugli, Alessandro ; Ramage, John ; Zwahlen, Marcel ; Perren, Aurel ; Kaderli, Reto M.LANCET ONCOLOGY.1.1.51,1.18.10.1016/S1470-2045(22)00750-1
  80. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.Cortellini, Alessio ; TABERNERO CATURLA, JOSEP; Mukherjee, Uma ; Salazar, Ramon ; Sureda, Anna ; Maluquer, Clara ; Ferrante, Daniela ; Bower, Mark ; Sharkey, Rachel ; MIRALLAS VIÑAS, ORIOL; Plaja, Andrea ; Cucurull, Marc ; Mesia, Ricard ; Dalla Pria, Alessia ; Newsom-Davis, Thomas ; Van Hemelrijck, Mieke ; Sita-Lumsden, Ailsa ; Apthorp, Eleanor ; Vincenzi, Bruno ; Fazio, Giuseppina Rita Di ; Tonini, Giuseppe ; Pantano, Francesco ; Bertuzzi, Alexia ; Rossi, Sabrina ; Brunet, Joan ; Lambertini, Matteo ; Pedrazzoli, Paolo ; Biello, Federica ; D’Avanzo, Francesca ; Lee, Alvin J. X. ; Shawe-Taylor, Marianne ; Rogers, Lucy ; Murphy, Cian ; Cooper, Lee ; Andaleeb, Ramis ; Khalique, Saira ; Bawany, Samira ; Ahmed, Sarah ; Carmona-Garcia, M. Carmen ; Fort-Culillas, Roser ; Linan, Raquel ; Zoratto, Federica ; Rizzo, Gianpiero ; Perachino, Marta ; Doonga, Kris ; Gaidano, Gianluca ; Bruna, Riccardo ; Patriarca, Andrea ; Martinez-Vila, Clara ; Criado, Ignacio Perez ; Giusti, Raffaele ; Mazzoni, Francesca ; Antonuzzo, Lorenzo ; Santoro, Armando ; Parisi, Alessandro ; Queirolo, Paola ; Aujayeb, Avinash ; Rimassa, Lorenza ; Diamantis, Nikolaos ; Bertulli, Rossella ; Fulgenzi, Claudia A. M. ; D’Alessio, Antonio ; Ruiz-Camps, Isabel ; SAOUDI GONZALEZ, NADIA; GARCIA ILLESCAS, DAVID; Medina, Irene ; FOX, M. LAURA; Gennari, Alessandra ; AGUILAR COMPANY, JUAN; Pinato, David J. ; OnCovid Study Grp.LANCET ONCOLOGY.1.1.51,1.9.10.1016/S1470-2045(23)00056-6
  81. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS  wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a  multicentre, open-label, phase 2 study..Strickler, John H ; Cercek, Andrea ; Siena, Salvatore ; André, Thierry ; Ng, Kimmie ; Van Cutsem, Eric ; Wu, Christina ; Paulson, Andrew S ; Hubbard, Joleen M ; Coveler, Andrew L ; Fountzilas, Christos ; Kardosh, Adel ; Kasi, Pashtoon M ; Lenz, Heinz-Josef ; Ciombor, Kristen K ; ELEZ FERNANDEZ, MARIA ELENA; Bajor, David L ; Cremolini, Chiara ; Sanchez, Federico ; Stecher, Michael ; Feng, Wentao ; Bekaii-Saab, Tanios S ; MOUNTAINEER investigators ; Van Cutsem, Eric ; Peeters, Marc ; Van den Evnde, Marc ; André, Thierry ; Borg, Christophe ; Sarabi, Matthieu ; Ghiringhelli, Francois ; Chibaudel, Benoist ; Siena, Salvatore ; Cremolini, Chiara ; Zampino, Maria G ; ELEZ FERNANDEZ, MARIA ELENA; Keranen, Susana R ; Salazar, Ramon ; Alfonso, Pilar ; Strickler, John H ; Cercek, Andrea ; Ng, Kimmie ; Wu, Christina ; Paulson, Andrew S ; Hubbard, Joleen M ; Coveler, Andrew L ; Fountzilas, Christos ; Kardosh, Adel ; Kasi, Pashtoon M ; Lenz, Heinz-Josef ; Ciombor, Kristen K ; Bajor, David L ; Bekaii-Saab, Tanios S ; Gbolahan, Olumide ; Boland, Patrick ; Berg, Daniel ; Sanchez, Federico ; Goggins, Timothy ; Saeed, Anwar ; Burris, Howard ; Bendell, Johanna ; Outlaw, Darryl ; Tafur, Isaac ; Shergill, Ardaman ; Catenacci, Daniel ; Gong, Jun ; Garrido-Laguna, Ignacio ; Finley, Gene ; Weinberg, Benjamin ; Shields, Anthony ; Philip, Philip ; Turk, Anita ; Nguyen, Anthony ; Braiteh, Fadi ; Patel, Vijay ; Harwin, William ; Anderson, Ian ; Kundra, Ajay ; Chen, Christopher ; Ford, James ; Kundranda, Madappa ; Nguyen, Danny ; Ratnam, Suresh ; Richards, Donald ; Nallapareddy, Sujatha ; Beeram, Sridhar ; McKenney, Scott ; Shao, Spencer.LANCET ONCOLOGY.1.1.51,1.22.10.1016/S1470-2045(23)00150-X
  82. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic  colorectal cancer treated with BRAF combinatorial treatments..ROS MONTAÑA, JAVIER; MATITO ARIZA, JUDIT; VILLACAMPA JAVIERRE, GUILLERMO; COMAS NAVARRO, RAQUEL; GARCIA RODRIGUEZ, ARIADNA MARIA; Martini, G ; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; Martin, Á ; Antista, M ; DE ALMEIDA TOLEDO, RODRIGO; Martinelli, E ; Pietrantonio, F ; Boccaccino, A ; Cremolini, C ; DIENSTMANN, RODRIGO; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; ELEZ FERNANDEZ, MARIA ELENA.ANNALS OF ONCOLOGY.1.1.50,5.8.10.1016/j.annonc.2023.02.016
  83. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus  Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic  Colorectal Cancer..Van Cutsem, Eric ; Taieb, Julien ; Yaeger, Rona ; Yoshino, Takayuki ; Grothey, Axel ; Maiello, Evaristo ; ELEZ FERNANDEZ, MARIA ELENA; Dekervel, Jeroen ; Ross, Paul ; Ruiz-Casado, Ana ; Graham, Janet ; Kato, Takeshi ; Ruffinelli, Jose C ; André, Thierry ; Carrière Roussel, Edith ; Klauck, Isabelle ; Groc, Mélanie ; Vedovato, Jean-Claude ; TABERNERO CATURLA, JOSEP.JOURNAL OF CLINICAL ONCOLOGY.1.1.45,4.19.10.1200/JCO.22.01693
  84. Early-Stage Breast Cancer Detection in Breast Milk..SAURA MANICH, CRISTINA; ORTIZ VELEZ, CAROLINA; MATITO ARIZA, JUDIT; ARENAS LAHUERTA, ENRIQUE HUERTA; SUÑOL CAMAS, ANNA; Martín, Ágatha ; Córdoba, Octavi ; MARTINEZ SABADELL, A; García-Ruiz, Itziar ; Miranda, Ignacio ; Morales-Comas, Clara ; CARRASCO LOPEZ, ESTELA; VIAPLANA DONATO, CRISTINA; PEG, VICENTE; NUCIFORO, PAOLO GIOVANNI; BAYO PUXAN, NEUS; Gonzalez-Medina, Alberto ; MIQUEL AYMAR, JOSEP MARIA; GOMEZ REY, MARINA; VILLACAMPA JAVIERRE, GUILLERMO; Arévalo, Silvia ; MUR ESPINOSA, ALEX; BALMAÑA GELPI, JUDITH; DIENSTMANN, RODRIGO; ARRIBAS LOPEZ, JOAQUIN VICENTE; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; SANSO MARTINEZ, MIRIAM.CANCER DISCOVERY.1.1.29,1.3.10.1158/2159-8290.CD-22-1340
  85. Hypoxia-Inducible Factor 2 Alpha (HIF2a) Inhibitors: Targeting Genetically Driven  Tumor Hypoxia..DE ALMEIDA TOLEDO, RODRIGO; Jimenez, Camilo ; Armaiz-Pena, Gustavo ; ARENILLAS LALLANA, CARLOTA; CAPDEVILA CASTILLON, JAUME; Dahia, Patricia L M.ENDOCRINE REVIEWS.1.1.20,3.9.10.1210/endrev/bnac025
  86. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine  neoplasms of gastroenteropancreatic and lung origin..CAPDEVILA, J ; HERNANDO CUBERO, JORGE; Teule, A ; Lopez, C ; Garcia-Carbonero, R ; Benavent, M ; Custodio, A ; GARCIA ALVAREZ, ALEJANDRO; Cubillo, A ; Alonso, V ; Carmona-Bayonas, A ; Alonso-Gordoa, T ; Crespo, G ; Jimenez-Fonseca, P ; Blanco, M ; Viudez, A ; La Casta, A ; Sevilla, I ; Segura, A ; Llanos, M ; LANDOLFI, STEFANIA; NUCIFORO, PAOLO GIOVANNI; Manzano, J L.NATURE COMMUNICATIONS.1.1.16,6.2.10.1038/s41467-023-38611-5
  87. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients  with HER2-expressing metastatic colorectal cancer..Yoshino, Takayuki ; Di Bartolomeo, Maria ; Raghav, Kanwal ; Masuishi, Toshiki ; Loupakis, Fotios ; Kawakami, Hisato ; Yamaguchi, Kensei ; Nishina, Tomohiro ; Wainberg, Zev ; ELEZ FERNANDEZ, MARIA ELENA; Rodriguez, Javier ; Fakih, Marwan ; Ciardiello, Fortunato ; Saxena, Kapil ; Kobayashi, Kojiro ; Bako, Emarjola ; Okuda, Yasuyuki ; Meinhardt, Gerold ; Grothey, Axel ; Siena, Salvatore ; DESTINY-CRC01 investigators ; Di Bartolomeo, Maria.NATURE COMMUNICATIONS.1.1.16,6.8.10.1038/s41467-023-38032-4
  88. Long-term platinum-based drug accumulation in cancer-associated fibroblasts  promotes colorectal cancer progression and resistance to therapy..Linares, Jenniffer ; Sallent-Aragay, Anna ; Badia-Ramentol, Jordi ; Recort-Bascuas, Alba ; Méndez, Ana ; Manero-Rupérez, Noemí ; Re, Daniele Lo ; Rivas, Elisa I ; Guiu, Marc ; Zwick, Melissa ; Iglesias, Mar ; Martinez-Ciarpaglini, Carolina ; Tarazona, Noelia ; Varese, Monica ; Hernando-Momblona, Xavier ; Cañellas-Socias, Adrià ; Orrillo, Mayra ; Garrido, Marta ; SAOUDI GONZALEZ, NADIA; ELEZ FERNANDEZ, MARIA ELENA; Navarro, Pilar ; TABERNERO CATURLA, JOSEP; Gomis, Roger R ; Batlle, Eduard ; Pisonero, Jorge ; Cervantes, Andres ; Montagut, Clara ; Calon, Alexandre.NATURE COMMUNICATIONS.1.1.16,6. .10.1038/s41467-023-36334-1
  89. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line  Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study..Vidal, Joana ; Fernández-Rodríguez, Maria Concepción ; Casadevall, David ; Garcia-Alfonso, Pilar ; Páez, David ; Guix, Marta ; Alonso, Vicente ; Cano, María Teresa ; Santos, Cristina ; Durán, Gema ; ELEZ FERNANDEZ, MARIA ELENA; Manzano, Jose Luis ; Garcia-Carbonero, Rocio ; Ferreiro-Monteagudo, Reyes ; Losa, Ferran ; Pineda, Estela ; Sastre, Javier ; Rivera, Fernando ; Bellosillo, Beatriz ; TABERNERO CATURLA, JOSEP; Aranda, Enrique ; Salazar, Ramon ; Montagut, Clara.CLINICAL CANCER RESEARCH.1.1.11,5.8.10.1158/1078-0432.CCR-22-1696
  90. Association of immune-related adverse events with the outcomes of immune  checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer..Nasca, Vincenzo ; Barretta, Francesco ; Corti, Francesca ; Lonardi, Sara ; Niger, Monica ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, Marwan ; Jayachandran, Priya ; Shah, Aakash Tushar ; Salati, Massimiliano ; Fenocchio, Elisabetta ; Salvatore, Lisa ; Cremolini, Chiara ; ROS MONTAÑA, JAVIER; Ambrosini, Margherita ; Mazzoli, Giacomo ; Intini, Rossana ; Overman, Michael J ; Miceli, Rosalba ; Pietrantonio, Filippo.Journal for ImmunoTherapy of Cancer.1.2.10,9.2.10.1136/jitc-2022-005493
  91. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year  results of GEMCAD-1402..Pesántez, David ; Ten Hoorn, Sanne ; Machado, Isidro ; García-Albéniz, Xabier ; Rodríguez-Salas, Nuria ; Heredia-Soto, Victoria ; Viñal, David ; Pericay, Carles ; García-Carbonero, Rocio ; Losa, Ferran ; Alonso, Vicente ; Vera, Ruth ; Feliu Batlle, Jaime ; Gallego, Javier ; Salud, Antonieta ; Nogué, Miquel ; Layos, Laura ; Montagut, Clara ; CAPDEVILA CASTILLON, JAUME; Vermeulen, Louis ; Maurel, Joan ; Fernandez-Martos, Carlos.JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.1.2.10,3. .10.1093/jnci/djad120
  92. Locoregional Failure During and After Short-course Radiotherapy Followed by  Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery:  A 5-Year Follow-up of the RAPIDO Trial..Dijkstra, Esmée A ; Nilsson, Per J ; Hospers, Geke A P ; Bahadoer, Renu R ; Meershoek-Klein Kranenbarg, Elma ; Roodvoets, Annet G H ; Putter, Hein ; Berglund, Åke ; Cervantes, Andrés ; Crolla, Rogier M P H ; Hendriks, Mathijs P ; CAPDEVILA CASTILLON, JAUME; Edhemovic, Ibrahim ; Marijnen, Corrie A M ; van de Velde, Cornelis J H ; Glimelius, Bengt ; van Etten, Boudewijn ; and collaborative investigators.ANNALS OF SURGERY.1.1.10,1.34.10.1097/SLA.0000000000005799
  93. Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of  different locations: data from the SEPTRALU study..Mitjavila, Mercedes ; Jimenez-Fonseca, Paula ; Belló, Pilar ; Pubul, Virginia ; Percovich, Juan Carlos ; Garcia-Burillo, Amparo ; HERNANDO CUBERO, JORGE; Arbizu, Javier ; Rodeño, Emilia ; Estorch, Montserrat ; Llana, Belén ; Castellón, Maribel ; García-Cañamaque, Lina ; Gajate, Pablo ; Riesco, Maria Carmen ; Miguel, Maria Begoña ; Balaguer-Muñoz, David ; Custodio, Ana ; Cano, Juana María ; Repetto, Alexandra ; Garcia-Alonso, Pilar ; Muros, Maria Angustias ; Vercher-Conejero, Jose Luis ; Carmona-Bayonas, Alberto.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.1.1.9,1.5.10.1007/s00259-023-06166-8
  94. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the  Spanish Registry of Essential Thrombocythemia..Alvarez-Larrán, Alberto ; Cuevas, Beatriz ; Velez, Patricia ; Noya, Soledad ; Caballero-Navarro, Gonzalo ; Ferrer-Marín, Francisca ; Carbonell, Sara ; Pérez-Encinas, Manuel ; Gómez-Casares, María Teresa ; Pérez-López, Raúl ; Magro, Elena ; Moretó, Ana ; Pastor-Galán, Irene ; Angona, Anna ; Mata-Vázquez, María Isabel ; Guerrero-Fernández, Lucía ; Guerra, José María ; Carreño-Tarragona, Gonzalo ; FOX, M. LAURA; Murillo, Ilda ; García-Gutiérrez, Valentín ; Mora, Elvira ; Stuckey, Ruth ; Arellano-Rodrigo, Eduardo ; Hernández-Boluda, Juan Carlos ; Pereira, Arturo.Hemasphere.1.2.9,1. .10.1097/HS9.0000000000000936
  95. Liver transplantation in metastatic colorectal cancer: are we ready for it?.ROS MONTAÑA, JAVIER; SALVA BALLABRERA, FRANCESC; Dopazo, Cristina ; López, Daniel ; SAOUDI GONZALEZ, NADIA; BARAIBAR ARGOTA, IOSUNE; Charco, Ramon ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.BRITISH JOURNAL OF CANCER.1.2.8,8.3.10.1038/s41416-023-02213-1
  96. DPPA3-HIF1a axis controls colorectal cancer chemoresistance by imposing a slow  cell-cycle phenotype..CUESTA BORRAS, ESTEFANIA; SALVANS GORJON, CANDIDA; ARQUES CASAMITJANA, ORIOL; CHICOTE RAMOS, IRENE; RAMIREZ CORPAS, LORENA; CABELLOS ALONSO, LAIA; MARTINEZ-QUINTANILLA MARTINEZ, JORDI; MUR ESPINOSA, ALEX; GARCIA ALVAREZ, ALEJANDRO; HERNANDO CUBERO, JORGE; Tejedor, Juan Ramón ; MIRALLAS VIÑAS, ORIOL; ELEZ FERNANDEZ, MARIA ELENA; Fraga, Mario F ; TABERNERO CATURLA, JOSEP; NUCIFORO, PAOLO GIOVANNI; CAPDEVILA CASTILLON, JAUME; GARCIA PALMER, HECTOR; PUIG BORREIL, ISABEL.CELL REPORTS.1.2.8,8.0.10.1016/j.celrep.2023.112927
  97. Efficacy and safety of immune checkpoint inhibitors in young adults with  metastatic melanoma..Wong, Selina K ; Blum, Steven M ; Sun, Xiaopeng ; Da Silva, Inês P ; Zubiri, Leyre ; Ye, Fei ; Bai, Kun ; Zhang, Kevin ; Ugurel, Selma ; Zimmer, Lisa ; Livingstone, Elisabeth ; Schadendorf, Dirk ; Serra-Bellver, Patricio ; MUÑOZ COUSELO, EVA; ORTIZ VELEZ, CAROLINA; LOSTES, MARIA JULIA; Huertas, Roberto M ; Arance, Ana ; Pickering, Lisa ; Long, Georgina V ; Carlino, Matteo S ; Buchbinder, Elizabeth I ; Vázquez-Cortés, Leticia ; Jara-Casas, Diego ; Márquez-Rodas, Iván ; González-Espinoza, Iván R ; Balko, Justin M ; Menzies, Alexander M ; Sullivan, Ryan J ; Johnson, Douglas B.EUROPEAN JOURNAL OF CANCER.1.2.8,4.3.10.1016/j.ejca.2022.12.013
  98. Pembrolizumab for previously treated, microsatellite instability-high/mismatch  repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164..Le, Dung T ; Diaz, Luis A Jr ; Kim, Tae Won ; Van Cutsem, Eric ; Geva, Ravit ; Jäger, Dirk ; Hara, Hiroki ; Burge, Matthew ; O’Neil, Bert H ; Kavan, Petr ; Yoshino, Takayuki ; Guimbaud, Rosine ; Taniguchi, Hiroya ; ELEZ FERNANDEZ, MARIA ELENA; Al-Batran, Salah-Eddin ; Boland, Patrick M ; Cui, Yi ; Leconte, Pierre ; Marinello, Patricia ; André, Thierry.EUROPEAN JOURNAL OF CANCER.1.2.8,4.8.10.1016/j.ejca.2023.02.016
  99. Sex differences on multikinase inhibitors toxicity in patients with advanced  gastroenteropancreatic neuroendocrine tumours..HERNANDO CUBERO, JORGE; ROCA HERRERA, MARIA; GARCIA ALVAREZ, ALEJANDRO; Raymond, Eric ; Ruszniewski, Philippe ; Kulke, Matthew H ; Grande, Enrique ; García-Carbonero, Rocío ; Castellano, Daniel ; Salazar, Ramón ; Ibrahim, Toni ; Teule, Alex ; Alonso, Vicente ; Fazio, Nicola ; Valle, Juan W ; Tafuto, Salvatore ; CARMONA HEREDIA, Mª ANGELES; NAVARRO GARCES, VICTOR; CAPDEVILA CASTILLON, JAUME.EUROPEAN JOURNAL OF CANCER.1.2.8,4.1.10.1016/j.ejca.2023.04.013
  100. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome  post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey..van Doesum, Jaap A ; Salmanton-García, Jon ; Marchesi, Francesco ; Di Blasi, Roberta ; Falces-Romero, Iker ; CABIRTA, ALBA; Farina, Francesca ; Besson, Caroline ; Weinbergerová, Barbora ; Van Praet, Jens ; Schönlein, Martin ; Lopez-Garcia, Alberto ; Lamure, Sylvain ; Guidetti, Anna ; De Ramón-Sánchez, Cristina ; Batinic, Josip ; Gavriilaki, Eleni ; Tragiannidis, Athanasios ; Tisi, Maria Chiara ; Plantefeve, Gaëtan ; Petzer, Verena ; Ormazabal-Velez, Irati ; Marques de Almeida, Joyce ; Marchetti, Monia ; Maertens, Johan A ; Machado, Marina ; Kulasekararaj, Austin G ; Hernández-Rivas, José Ángel ; Gomes da Silva, Maria ; Fernández, Noemí ; Espigado, Ildefonso ; Drgona, Lubos ; Dragonetti, Giulia ; Metafuni, Elisabetta ; Calbacho, Maria ; Blennow, Ola ; Wolf, Dominik ; van Anrooij, Bjorn ; Nunes Rodrigues, Raquel ; Nordlander, Anna ; Martín-González, Juan-Alberto ; Lievin, Raphaël ; JIMENEZ BALAREZO, MARIA MORAIMA DEL CARMEN; Grafe, Stefanie K ; Garcia-Sanz, Ramon ; Córdoba, Raúl ; Rahimli, Laman ; van Meerten, Tom ; Cornely, Oliver A ; Pagano, Livio.Blood Advances.1.2.7,6.7.10.1182/bloodadvances.2022009578
  101. A signature of circulating microRNAs predicts the response to treatment with  FOLFIRI plus aflibercept in metastatic colorectal cancer patients..Toledano-Fonseca, M ; Gómez-España, M A ; ELEZ FERNANDEZ, MARIA ELENA; Grávalos, C ; García-Alfonso, P ; Rodríguez, R ; Losa, F ; Alés Díaz, I ; Graña, B ; Valladares-Ayerbes, M ; García-Ortiz, M V ; Polo, E ; Salgado, M ; Rivera, F ; Safont, M J ; Salud, A ; Ruiz-Casado, A ; TABERNERO CATURLA, JOSEP; Riesco, M C ; Rodríguez-Ariza, A ; Aranda, E ; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).BIOMEDICINE & PHARMACOTHERAPY.1.1.7,5.2.10.1016/j.biopha.2023.114272
  102. Establishment of patient-derived tumor organoids to functionally inform treatment  decisions in metastatic colorectal cancer..Martini, G ; Belli, V ; Napolitano, S ; Ciaramella, V ; Ciardiello, D ; Belli, A ; Izzo, F ; Avallone, A ; Selvaggi, F ; Menegon Tasselli, F ; Santaniello, W ; Franco, R ; PUIG BORREIL, ISABEL; RAMIREZ CORPAS, LORENA; CHICOTE RAMOS, IRENE; MANCUSO, FRANCESCO MATTIA; CARATU, GINEVRA; Serres, X ; FASANI, ROBERTA; JIMENEZ, JOSE; ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; Mulet, N ; Della Corte, C M ; Troiani, T ; VIVANCOS PRELLEZO, ANA; DIENSTMANN, RODRIGO; ELEZ FERNANDEZ, MARIA ELENA; GARCIA PALMER, HECTOR; TABERNERO CATURLA, JOSEP; Martinelli, E ; Ciardiello, F ; ARGILES MARTINEZ, GUILLERMO.ESMO open.1.2.7,3.5.10.1016/j.esmoop.2023.101198
  103. Sex and gender perspectives in colorectal cancer..BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; GARCIA RODRIGUEZ, ARIADNA MARIA; RODRIGUEZ CASTELLS, MARTA; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.ESMO open.1.2.7,3.9.10.1016/j.esmoop.2023.101204
  104. The value of post-operative chemotherapy after chemoradiotherapy in patients with  high-risk locally advanced rectal cancer-results from the RAPIDO trial..Dijkstra, E A ; Zwart, W H ; Nilsson, P J ; Putter, H ; Roodvoets, A G H ; Meershoek-Klein Kranenbarg, E ; Frödin, J E ; Nygren, P ; Østergaard, L ; Kersten, C ; Verbiené, I ; Cervantes, A ; Hendriks, M P ; CAPDEVILA CASTILLON, JAUME; Edhemovic, I ; van de Velde, C J H ; Marijnen, C A M ; van Etten, B ; Hospers, G A P ; Glimelius, B ; collaborative investigators.ESMO open.1.2.7,3.1.10.1016/j.esmoop.2023.101158
  105. Genomically matched therapy in refractory colorectal cancer according to ESMO  Scale for Clinical Actionability of Molecular Targets: experience of a  comprehensive cancer centre network..Margalef, Núria Mulet ; Castillo, Carmen ; Mosteiro, Miguel ; Pérez, Xavier ; AGUILAR IZQUIERDO, SUSANA; RUIZ PACE, FIORELLA DAFNE; Gil, Marta ; Cuadra, Carmen ; Ruffinelli, José Carlos ; Martínez, Mercedes ; Losa, Ferran ; Soler, Gema ; Teulé, Àlex ; Castany, Roser ; Gallego, Rosa ; Ruíz, Andrea ; GARRALDA CABANAS, ELENA; ELEZ FERNANDEZ, MARIA ELENA; VIVANCOS PRELLEZO, ANA; TABERNERO CATURLA, JOSEP; Salazar, Ramon ; DIENSTMANN, RODRIGO; Santos, Cristina.MOLECULAR ONCOLOGY.1.3.6,6.0.10.1002/1878-0261.13444
  106. Efficacy and safety of pembrolizumab monotherapy in patients with advanced  thyroid cancer in the phase 2 KEYNOTE-158 study..Oh, Do-Youn ; Algazi, Alain ; CAPDEVILA CASTILLON, JAUME; Longo, Federico ; Miller, Wilson Jr ; Chun Bing, Jerry Tan ; Bonilla, Carlos Eduardo ; Chung, Hyun Cheol ; Guren, Tormod K ; Lin, Chia-Chi ; Motola-Kuba, Daniel ; Shah, Manisha ; Hadoux, Julien ; Yao, Lili ; Jin, Fan ; Norwood, Kevin ; Lebellec, Loïc.CANCER.1.3.6,2.4.10.1002/cncr.34657
  107. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell  vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal  cancer patients; GEMCAD 1602 study..Español-Rego, Marta ; Fernández-Martos, Carlos ; ELEZ FERNANDEZ, MARIA ELENA; Foguet, Carles ; Pedrosa, Leire ; Rodríguez, Nuria ; Ruiz-Casado, Ana ; Pineda, Estela ; Cid, Joan ; Cabezón, Raquel ; Oliveres, Helena ; Lozano, Miquel ; Ginés, Angels ; García-Criado, Angeles ; Ayuso, Juan Ramon ; Pagés, Mario ; Cuatrecasas, Miriam ; Torres, Ferràn ; Thomson, Timothy ; Cascante, Marta ; Benítez-Ribas, Daniel ; Maurel, Joan.CANCER IMMUNOLOGY IMMUNOTHERAPY.1.3.5,8.3.10.1007/s00262-022-03283-5
  108. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF  V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer..TABERNERO CATURLA, JOSEP; Van Cutsem, Eric ; GARRALDA CABANAS, ELENA; Tai, David ; De Braud, Filippo ; Geva, Ravit ; van Bussel, Mark T J ; Fiorella Dotti, Katia ; Elez, Elena ; de Miguel, María J ; Litwiler, Kevin ; Murphy, Danielle ; Edwards, Michelle ; Morris, Van Karlyle.ONCOLOGIST.1.3.5,8.7.10.1093/oncolo/oyad007
  109. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR  Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors..Colle, Raphael ; Lonardi, Sara ; Cachanado, Marine ; Overman, Michael J ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, Marwan ; Corti, Francesca ; Jayachandran, Priya ; Svrcek, Magali ; Dardenne, Antoine ; Cervantes, Baptiste ; Duval, Alex ; Cohen, Romain ; Pietrantonio, Filippo ; André, Thierry.ONCOLOGIST.1.3.5,8.5.10.1093/oncolo/oyad082
  110. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus  Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer..Van Cutsem, Eric ; Yaeger, Rona ; Delord, Jean-Pierre ; TABERNERO CATURLA, JOSEP; Siu, Lillian L ; Ducreux, Michel ; Siena, Salvatore ; ELEZ FERNANDEZ, MARIA ELENA; Kasper, Stefan ; Zander, Thomas ; Steeghs, Neeltje ; Murphy, Danielle ; Edwards, Michelle ; Wainberg, Zev A.ONCOLOGIST.1.3.5,8.0.10.1093/oncolo/oyad210
  111. Pembrolizumab in Asian patients with  microsatellite-instability-high/mismatch-repair-deficient colorectal cancer..Yoshino, Takayuki ; Andre, Thierry ; Kim, Tae Won ; Yong, Wei Peng ; Shiu, Kai-Keen ; Jensen, Benny Vittrup ; Jensen, Lars Henrik ; Punt, Cornelis J A ; Smith, Denis ; Garcia-Carbonero, Rocio ; Alcaide-Garcia, Julia ; Gibbs, Peter ; de la Fouchardiere, Christelle ; Rivera, Fernando ; ELEZ FERNANDEZ, MARIA ELENA; Le, Dung T ; Adachi, Noriaki ; Fogelman, David ; Marinello, Patricia ; Diaz, Luis A Jr.CANCER SCIENCE.2.3.5,7.4.10.1111/cas.15650
  112. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The  Ongoing Search for Biomarkers..ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; Rodriguez, Marta ; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Cancers.2.3.5,2.2.10.3390/cancers15174245
  113. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution,  and Clinical Implications..SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; RODRIGUEZ CASTELLS, MARTA; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaráz, Adriana ; Vega, Sharela ; Bueno, Sergio ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Cancers.2.3.5,2.0.10.3390/cancers15164020
  114. Impact of the COVID-19 pandemic in the early-onset colorectal cancer..BARAIBAR ARGOTA, IOSUNE; GARCIA RODRIGUEZ, ARIADNA MARIA; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; COMAS NAVARRO, RAQUEL; Castillo, Gloria ; Sanchis, Mireia ; GARCIA ALVAREZ, ALEJANDRO; HERNANDO CUBERO, JORGE; CAPDEVILA CASTILLON, JAUME; Castells, Marta R ; Martí, Marc ; LANDOLFI, STEFANIA; Espín, Eloy ; Navalpotro, Begoña ; Guevara, Jorge ; Dopazo, Cristina ; NUCIFORO, PAOLO GIOVANNI; VIVANCOS PRELLEZO, ANA; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Translational Oncology.2.4.5.1.10.1016/j.tranon.2023.101668
  115. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line  Treatment..Andreatos, Nikolaos ; McGarrah, Patrick W ; Sonbol, Mohamad Bassam ; Starr, Jason S ; CAPDEVILA CASTILLON, JAUME; Sorbye, Halfdan ; Halfdanarson, Thorvardur R.CURRENT ONCOLOGY REPORTS.2.4.4,7.0.10.1007/s11912-023-01438-w
  116. Use of lenvatinib in the treatment of radioiodine-refractory differentiated  thyroid cancer: a multidisciplinary perspective for daily practice..CAPDEVILA CASTILLON, JAUME; Deandreis, Desiree’ ; Durante, Cosimo ; Leboulleux, Sophie ; Luster, Markus ; Netea-Maier, Romana ; Newbold, Kate ; Singer, Susanne ; Sykiotis, Gerasimos P ; Bartes, Beate ; Farnell, Kate ; Locati, Laura Deborah.European Thyroid Journal.2.3.4,7.0.10.1530/ETJ-23-0068
  117. Advances in immune checkpoint inhibitor combination strategies for microsatellite  stable colorectal cancer..ROS MONTAÑA, JAVIER; Balconi, Francesca ; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Frontiers in oncology.2.4.4,7.9.10.3389/fonc.2023.1112276
  118. Current perspectives on the management of patients with advanced RET-driven  thyroid cancer in Europe..Elisei, Rossella ; Grande, Enrique ; Kreissl, Michael C ; Leboulleux, Sophie ; Puri, Tarun ; Fasnacht, Nicolas ; CAPDEVILA CASTILLON, JAUME.Frontiers in oncology.2.4.4,7.1.10.3389/fonc.2023.1141314
  119. The impact of clinical and translational research on the quality of life during  the metastatic colorectal cancer patient journey..RODRIGUEZ CASTELLS, MARTA; BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaraz, Adriana ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Frontiers in oncology.2.4.4,7.0.10.3389/fonc.2023.1272561
  120. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch  Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer  Treated With Target Therapy or Chemotherapy..Moretto, Roberto ; Germani, Marco Maria ; ROS MONTAÑA, JAVIER; Daniel, Francesca ; Ghelardi, Filippo ; Vetere, Guglielmo ; Giordano, Mirella ; DE ALMEIDA TOLEDO, RODRIGO; Bergamo, Francesca ; Randon, Giovanni ; ELEZ FERNANDEZ, MARIA ELENA; Lonardi, Sara ; Pietrantonio, Filippo ; Vignali, Paola ; Rossini, Daniele ; MATITO ARIZA, JUDIT; Ugolini, Clara ; Fontanini, Gabriella ; Masi, Gianluca ; Cremolini, Chiara.Jco Precision Oncology.2.4.4,6. .10.1200/PO.23.00255
  121. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the  INTENSIVE study..Fazio, Nicola ; Gervaso, Lorenzo ; Halfdanarson, Thorvardur R ; Sonbol, Mohamad ; Eiring, Rachel A ; Pusceddu, Sara ; Prinzi, Natalie ; Lombardi Stocchetti, Benedetta ; Grozinsky-Glasberg, Simona ; Gross, David J ; Walter, Thomas ; Robelin, Patrick ; Lombard-Bohas, Catherine ; Frassoni, Samuele ; Bagnardi, Vincenzo ; Antonuzzo, Lorenzo ; Sparano, Clotilde ; Massironi, Sara ; Gelsomino, Fabio ; Bongiovanni, Alberto ; Ranallo, Nicoletta ; Tafuto, Salvatore ; Rossi, Maura ; Cives, Mauro ; Rasul Kakil, Ibrahim ; Hamid, Hytam ; Chirco, Alessandra ; Squadroni, Michela ; La Salvia, Anna ; HERNANDO CUBERO, JORGE; Hofland, Johannes ; Koumarianou, Anna ; Boselli, Sabrina ; Tamayo, Darina ; Mazzon, Cristina ; Rubino, Manila ; Spada, Francesca.ENDOCRINE-RELATED CANCER.2.5.3,9.0.10.1530/ERC-22-0395
  122. Current professional standing of young medical oncologists in Spain: a nationwide  survey by the Spanish Society of Medical Oncology + MIR section..Martinez, Domingo Antonio Sanchez ; Quilez-Cutillas, Aliica ; Jimenez-Labaig, Pablo ; Sesma, Andrea ; Tarazona, Noelia ; Pacheco-Barcia, Vilma ; Obispo, Berta ; Paez, David ; Quintanar, Teresa ; Sanchez-Canovas, Manuel ; Montes, Ana Fernandez ; FELIP FONT, ENRIQUETA; Rodriguez-Lescure, Alvaro ; ELEZ FERNANDEZ, MARIA ELENA.CLINICAL & TRANSLATIONAL ONCOLOGY.3.6.3,4.1.10.1007/s12094-022-02989-3
  123. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and  biomarkers..ROS MONTAÑA, JAVIER; RODRIGUEZ CASTELLS, MARTA; SAOUDI GONZALEZ, NADIA; BARAIBAR ARGOTA, IOSUNE; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.EXPERT REVIEW OF ANTICANCER THERAPY.3.6.3,3.3.10.1080/14737140.2023.2236794
  124. Satisfaction with injection experience of patients with neuroendocrine tumors  enrolled on lanreotide autogel patient support programs: Results from the  international HomeLAN survey..HERNANDO CUBERO, JORGE; Kolarova, Teodora ; Verslype, Chris ; Kaltsas, Gregory ; Houchard, Aude ; Gueguen, Delphine ; De Herder, Wouter W.JOURNAL OF NEUROENDOCRINOLOGY.3.6.3,2.0.10.1111/jne.13281
  125. Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study.Grande, Enrique ; Moreno, Fernando ; Trigo, Jose ; CAPDEVILA CASTILLON, JAUME; Abiles, Jimena ; Sirvent, Mariola ; Garrido-Siles, Margarita ; Olveira, Gabriel ; Ocon, Julia ; Soto, Maria Luisa Fernandez.SUPPORTIVE CARE IN CANCER.1.3.3,1.0.10.1007/s00520-023-08004-x
  126. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize  immuno-oncology combinations in early-phase trials..HERNANDO CALVO, ALBERTO; VILA CASADESUS, MARIA; Bareche, Yacine ; Gonzalez-Medina, Alberto ; Abbas-Aghababazadeh, Farnoosh ; LO GIACCO, DEBORA GRAZIA; MARTIN CASADO, AGATHA; SAAVEDRA SANTAGADEA, OMAR; BRAÑA GARCIA, IRENE; VIEITO VILLAR, MARIA; FASANI, ROBERTA; Stagg, John ; MANCUSO, FRANCESCO MATTIA; Haibe-Kains, Benjamin ; Han, Ming ; BERCHE BARCELO, ROGER; Pugh, Trevor J ; MIRALLAS VIÑAS, ORIOL; JIMENEZ, JOSE; SAOUDI GONZALEZ, NADIA; VALVERDE MORALES, CLAUDIA M; MUÑOZ COUSELO, EVA; SUAREZ RODRIGUEZ, CRISTINA; DIEZ GARCIA, MARC; ELEZ FERNANDEZ, MARIA ELENA; CAPDEVILA CASTILLON, JAUME; OAKNIN BENZAQUEN, ANA MAZALTOB; SAURA MANICH, CRISTINA; MACARULLA MERCADE, TERESA; CARLES GALCERAN, JOAN; FELIP FONT, ENRIQUETA; DIENSTMANN, RODRIGO; Bedard, Philippe L ; NUCIFORO, PAOLO GIOVANNI; SEOANE SUAREZ, JOAN; TABERNERO CATURLA, JOSEP; GARRALDA CABANAS, ELENA; VIVANCOS PRELLEZO, ANA.Med. . . .0.10.1016/j.medj.2023.07.006
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required